Physician profile
Vivek Kumar Jain
NPI 1487649687
$5,503.08
in general payments reported to CMS, 2019-2025
32 companies · $1,378 in 2025
The $1,378 reported for 2025 was more than what 83% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $592 · 2020: $325 · 2021: $131 · 2022: $824 · 2023: $1,181 · 2024: $1,073 · 2025: $1,378.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,606 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,606.04 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,633.48 | 2019-2025 | Ngenuity, Clareon, Ora System Verifeye |
| Abbvie INC. | $504.25 | 2023-2025 | |
| Glaukos Corporation | $397.08 | 2022-2025 | Idosetr, Kxl System (Not Refurbished), Photrexa Viscous and Photrexa |
| Rayner Intraocular Lenses Limited | $325.93 | 2022-2025 | Rayone Spheric, Rayone Emv, Rayone Aspheric |
| Ocular Therapeutix, INC. | $315.54 | 2019-2025 | Dextenza |
| Tarsus Pharmaceuticals, INC. | $310.21 | 2024-2025 | Xdemvy |
| New World Medical,INC. | $252.87 | 2022-2023 | |
| Mallinckrodt Hospital Products INC. | $190.98 | 2020-2022 | |
| Rxsight INC | $176.64 | 2023 | Rxsight Injector Handpiece, Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Bausch & Lomb Americas INC. | $147.01 | 2023-2025 | Envista Envy Iol, Miebo, Xiidra |
| Dompe US, INC. | $122.91 | 2019-2025 | Oxervate |
| Biotissue Holdings INC. | $120.65 | 2022-2025 | |
| Harrow Eye, LLC | $98.40 | 2024-2025 | Vevye |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $95.98 | 2019 | |
| Sight Sciences, INC. | $90.85 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $89.06 | 2019-2021 | |
| Oyster Point Pharma, INC. | $81.31 | 2023-2024 | Tyrvaya |
| Amgen INC. | $74.93 | 2024-2025 | Tepezza |
| Aerie Pharmaceuticals, INC. | $65.42 | 2019-2020 | |
| Johnson & Johnson Surgical Vision, INC. | $57.51 | 2019-2022 | |
| Leadiant Biosciences, INC. | $50.29 | 2025 | Cystaran |
| Sun Pharmaceutical Industries INC. | $46.87 | 2019-2025 | |
| Thea Pharma INC. | $40.56 | 2023-2025 | Iyuzeh |
| Mallinckrodt Enterprises LLC | $39.17 | 2019 | |
| Carl Zeiss Meditec, INC. | $37.54 | 2019 | |
| Oasis Medical, INC. | $24.27 | 2021 | |
| Dutch Ophthalmic, USA | $24.18 | 2024 | Tissueblue, Eva, Combined Machine |
| Novartis Pharmaceuticals Corporation | $24.15 | 2023 | |
| Kala Pharmaceuticals, INC. | $18.11 | 2019 | |
| Horizon Therapeutics Plc | $16.90 | 2023 | Tepezza |
| Quidel Corporation | $15.13 | 2023 | |
| Eyevance Pharmaceuticals LLC | $14.90 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vivek Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.